MoonLake Immunotherapeutics Investor Relations Material
Latest events
CMD 2025
MoonLake Immunotherapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from MoonLake Immunotherapeutics
Access all reports
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company, focusing on the development of innovative therapies for inflammatory diseases. The company is advancing Sonelokimab, a novel investigational Nanobody, to address conditions such as hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and axial spondyloarthritis. MoonLake Immunotherapeutics aims to leverage the therapeutic potential of Sonelokimab to meet significant unmet medical needs in the treatment of these diseases. MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, and its shares are listed on the NASDAQ.
Key slides for MoonLake Immunotherapeutics
CMD 2025
MoonLake Immunotherapeutics
CMD 2024
MoonLake Immunotherapeutics
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
MLTX
Country
🇺🇸 United States